BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Everest Medicines Doses First Patient with AI-Driven Personalized mRNA Cancer Vaccine EVM16 in Landmark Clinical Trial

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...

March 07, 2025 | News

GenAssist Gains FDA IND Clearance for First-in-Class Base Editing Therapy for Duchenne Muscular Dystrophy

GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company specializing in genome medicines, is thrilled to announce that it has received&n...

March 07, 2025 | News

CStone Pharmaceuticals Doses First Patient in Global Phase I Trial of Trispecific Antibody CS2009

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

March 05, 2025 | News

Raziel Therapeutics Launches Phase 3 Study in China for RZL-012, an Injectable Fat Reduction Treatment

Raziel Therapeutics, a pharmaceutical company developing next-generation novel prescription products for the medical aesthetics market, announces phas...

March 05, 2025 | News

WuXi Biologics Introduces EffiX™ a High-Yield E. coli Expression Platform for Recombinant Proteins and Plasmid DNA Production

EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. ...

March 04, 2025 | News

China Fapon Biopharma secures US FDA IND approval for FP008 a first-in-class immunocytokine for resistant solid tumors

Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administr...

March 03, 2025 | News

Alphamab Oncology and CSPC Dose First Patient in Phase III Trial of JSKN003 for HER2-Positive Breast Cancer

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has...

February 28, 2025 | News

WuXi Biologics Passes Japan’s PMDA GMP Inspection for Wuxi Drug Substance Facilities

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has...

February 28, 2025 | News

CARsgen Doses First SLE Patient with KJ-C2219, a Dual-Target Allogeneic CAR-T Therapy

CARsgen Therapeutics Holdings Limited a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tu...

February 28, 2025 | News

Ping An Health Launches AI-Powered "Ping An Xin Yi" Digital Doctor for 24/7 Smart Healthcare

Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently annou...

February 27, 2025 | News

Fosun Pharma Secures NMPA Approval for Tenapanor, Bringing New Hope to Dialysis Patients in China

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharm...

February 27, 2025 | News

ZEISS’s Next-Generation VISUMAX® 800 with SMILE® Pro Secures NMPA Approval for Laser Vision Correction in China

ZEISS Medical Technology announced that the National Medical Products Administration (NMPA) in China has approved the VISUMAX® 800 with ...

February 27, 2025 | News

Biocair Opens a New Site in Chengdu, China

The new site marks Biocair’s eighth location in the Asia-Pacific region. Biocair reinforces the importance of de...

February 26, 2025 | News

WuXi XDC Expands Partnership with LigaChem to Accelerate Next-Gen ADC Development

WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organiz...

February 26, 2025 | News

Stay Connected